Bon week-end a toutes/tous

Hello des idées d'achats..$ FTR  $ YTRA 👀

ACADIA Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for NUPLAZID® (Pimavanserin) | Business Wire

ACADIA Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for NUPLAZID® (Pimavanserin) | Business Wire: ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced FDA approval of a new capsule dose formulation and a new tablet strength of NUPLAZID (pimav

U.S. Dialysis Catheter Market Analysis & Outlook to 2024 - MedCore - ResearchAndMarkets.com | Business Wire

U.S. Dialysis Catheter Market Analysis & Outlook to 2024 - MedCore - ResearchAndMarkets.com | Business Wire: The

22nd Century宣布新的非转基因极低尼古丁烤烟和白肋烟变种 | Business Wire

22nd Century宣布新的非转基因极低尼古丁烤烟和白肋烟变种 | Business Wire: (美国商业资讯) -- 22nd Century Group, Inc. (NYSE American: XXII) 是一家植物生物技术公司，也是烟草减害和极低尼古丁烟草领域的领导者。公司今天宣布，已从北卡罗莱纳州立大学(NCSU)获得若干种尼古丁含量极低的烤烟和白肋烟植物品系的排他性授权。上述新植

PharmaCyte Biotech Discusses Importance of Shrinking Pancreatic Cancer Tumors in Latest Q

PharmaCyte Biotech Discusses Importance of Shrinking Pancreatic Cancer Tumors in Latest Q: PharmaCyte Biotech Discusses Importance of Shrinking Pancreatic Cancer Tumors

recommandations

26/06/2018 | 08:56

    PARIS, 26 juin (Reuters) - Principaux changements de recommandations et/ou d'objectifs de
cours enregistrés mardi à Paris:
    
    * RENAULT           - Morgan Stanley a relevé sa recommandation à "pondération en ligne"
contre "sous-pondérer", avec un objectif de cours de 88 euros. 
    
    * DASSAULT SYSTEMES           - UBS, à "vendre" sur la valeur, a relevé son objectif de
cours à 112 euros contre 87,50 euros.
    
    * ARKEMA          - Barclays, à "surpondérer" sur la valeur, a abaissé son objectif de cours
à 121 euros contre 128 euros. 
    
    * ERYTECH PHARMA           - Jefferies, à l'achat sur la valeur, a abaissé son objectif de
cours à 36 euros contre 39 euros.

Veritas Appoints Mr. Filios Theodorou as Its Agent for Cyprus and SEMEA Countries

Veritas Appoints Mr. Filios Theodorou as Its Agent for Cyprus and SEMEA Countries

Insulet Presents Positive Clinical Trial Results for the Omnipod® Horizon™ Hybrid Closed-Loop System at the American Diabetes Association's 78th Scientific Sessions | Business Wire

Insulet Presents Positive Clinical Trial Results for the Omnipod® Horizon™ Hybrid Closed-Loop System at the American Diabetes Association's 78th Scientific Sessions | Business Wire: Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System

Dashboard - Meine Einschätzungen - sharewise.com

Dashboard - Meine Einschätzungen - sharewise.com

Medtronic Announces Second Bone Cement Solution Indicated for Treating Sacral Fractures

Medtronic Announces Second Bone Cement Solution Indicated for Treating Sacral Fractures

22nd Century Conducts Three Short-Term Studies in Support of the Company’s MRTP Application to the FDA | Business Wire

22nd Century Conducts Three Short-Term Studies in Support of the Company’s MRTP Application to the FDA | Business Wire: 22nd Century Conducts Three Short-Term Studies in Support of the Company’s MRTP Application to the FDA; Details available at www.clinicaltrials.gov

ＰＨＣホールディングス株式会社：薬剤師の業務効率化を目指した保険薬局用電子薬歴システム「PharnesV-MX」を販売開始 | Business Wire

ＰＨＣホールディングス株式会社：薬剤師の業務効率化を目指した保険薬局用電子薬歴システム「PharnesV-MX」を販売開始 | Business Wire: （ビジネスワイヤ） -- PHCホールディングス株式会社（本社：東京都港区）の100%子会社である、PHC株式会社（以下「PHC」）は、このたび、保険薬局用電子薬歴システム「PharnesV-MX」を発売しましたので、お知らせします。 PharnesV-MXは、薬剤師の業務改善を目指した新しい電子薬

Shire plc : Rule 2.9 Announcement

Shire plc : Rule 2.9 Announcement

ITM: FDA Acceptance of IND to Advance Phase III Clinical Trial COMPETE with Solucin® for Treatment of GEP-NET in the U.S. | Business Wire

ITM: FDA Acceptance of IND to Advance Phase III Clinical Trial COMPETE with Solucin® for Treatment of GEP-NET in the U.S. | Business Wire: ITM announced today that the U.S. FDA has accepted the Investigational New Drug Application to advance its radiopharmaceutical to a phase III trial

Insulet to Unveil New Omnipod® DASHTM System and Present Innovative Research at the American Diabetes Association's 78th Scientific Sessions | Business Wire

Insulet to Unveil New Omnipod® DASHTM System and Present Innovative Research at the American Diabetes Association's 78th Scientific Sessions | Business Wire: Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management Syste

ObsEva's EDELWEISS Trial Hits All Goals In Endometriosis-associated Pain

ObsEva's EDELWEISS Trial Hits All Goals In Endometriosis-associated Pain

ImmunoGen Announces FDA Fast Track Designation for Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer | Business Wire

ImmunoGen Announces FDA Fast Track Designation for Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer | Business Wire: ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that t

BioTrace Medical Announces Key Events Featuring Tempo® Lead at TVT 2018 | Business Wire

BioTrace Medical Announces Key Events Featuring Tempo® Lead at TVT 2018 | Business Wire: BioTrace Medical, Inc., the leader in innovative temporary pacing technology, today announced the company’s key activities at the Transcatheter Valve

Bonne fête des papas

Cerus Presents Results of European Phase 3 Chronic Anemia Study at the 23rd Congress of European Hematology Association | Business Wire

Cerus Presents Results of European Phase 3 Chronic Anemia Study at the 23rd Congress of European Hematology Association | Business Wire: Cerus Corporation (Nasdaq: CERS) announced that results from SPARC, the Company’s European Phase 3 study evaluating the efficacy and safety of INTERCE

Global Healthcare Contract Research and Manufacturing Outsourcing Market to Post a CAGR of 12% | Technavio | Business Wire

Global Healthcare Contract Research and Manufacturing Outsourcing Market to Post a CAGR of 12% | Technavio | Business Wire: The global healthcare contract research and manufacturing outsourcing market is set to post a CAGR of almost 12% until 2022, according to Technavio.

DIAXONHIT DEVIENT EUROBIO SCIENTIFIC : Changement de nom adopté à l'Assemblée Générale Annuelle

DIAXONHIT DEVIENT EUROBIO SCIENTIFIC : Changement de nom adopté à l'Assemblée Générale Annuelle

Trillium Therapeutics Doses First Patient With TTI-622, Its Second Immune Checkpoint Inhibitor Targeting CD47

Trillium Therapeutics Doses First Patient With TTI-622, Its Second Immune Checkpoint Inhibitor Targeting CD47

Elite Pharmaceuticals, Inc. Announces Passing of Board Member Eugene Pfeifer

Elite Pharmaceuticals, Inc. Announces Passing of Board Member Eugene Pfeifer

FDA Clears Gold Standard Diagnostics’ Borrelia burgdorferi IgG/IgM ELISA Assay | Business Wire

FDA Clears Gold Standard Diagnostics’ Borrelia burgdorferi IgG/IgM ELISA Assay | Business Wire: Gold Standard Diagnostics, Corp. today announced the U.S. Food and Drug Administration issued a 510(k) clearance for its Borrelia burgdorferi IgG/IgM

Global Disposable Blood Bag Market Analysis & Industry Forecast 2017-2023, With an Expected CAGR of 11% - ResearchAndMarkets.com | Business Wire

Global Disposable Blood Bag Market Analysis & Industry Forecast 2017-2023, With an Expected CAGR of 11% - ResearchAndMarkets.com | Business Wire: The

ExThera Medical gibt Abschluss von Studie zur Bewertung der Sicherheit des Blutfilters Seraph® 100 für die Registrierung der CE-Kennzeichnung bekannt | Business Wire

ExThera Medical gibt Abschluss von Studie zur Bewertung der Sicherheit des Blutfilters Seraph® 100 für die Registrierung der CE-Kennzeichnung bekannt | Business Wire: Die ExThera Medical Corporation, ein Entwickler von Therapien für die Entfernung von Bakterien und Viren aus dem Blut, hat heute den Abschluss ihrer S

Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | Business Wire

Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | Business Wire: Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease throug

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS Greater Than or Equal to 1) | Business Wire

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS Greater Than or Equal to 1) | Business Wire: FDA Approves Merck’s KEYTRUDA for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1

Los resultados del estudio fase III OPTIMISMM presentados en ASCO 2018 mostraron que el triplete PVd mejoraba la SLP en líneas precoces del mieloma múltiple recidivante o refractario | Business Wire

Los resultados del estudio fase III OPTIMISMM presentados en ASCO 2018 mostraron que el triplete PVd mejoraba la SLP en líneas precoces del mieloma múltiple recidivante o refractario | Business Wire: Celgene Corporation (NASDAQ: CELG) anunció hoy los resultados del estudio OPTIMISMM, un ensayo clínico fase III, internacional, aleatorizado, abierto,

ExThera Medical annonce la conclusion de l'essai d'homologation du marquage CE visant à évaluer la sécurité d'emploi du filtre à sang Seraph® 100 | Business Wire

ExThera Medical annonce la conclusion de l'essai d'homologation du marquage CE visant à évaluer la sécurité d'emploi du filtre à sang Seraph® 100 | Business Wire: ExThera Medical Corporation, qui développe des traitements visant à éliminer les bactéries et virus du sang, a annoncé aujourd'hui la conclusion de l'

ContraVir Pharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of Record

ContraVir Pharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of Record

リヴァノヴァの無縫合大動脈心臓弁パーシバルが日本で承認される | Business Wire

リヴァノヴァの無縫合大動脈心臓弁パーシバルが日本で承認される | Business Wire: 市場をリードする医療技術企業のリヴァノヴァ（NASDAQ:LIVN）（「リヴァノヴァ」または「当社」）は本日、大動脈弁疾患を治療するための当社の無縫合大動脈心臓弁Perceval®（パーシバル）を日本の厚生労働省が承認したと発表しました。 リヴァノヴァ株式会社の川名範明社長は、次のように述べています

Agilent Enables CISH on Dako Omnis | Business Wire

Agilent Enables CISH on Dako Omnis | Business Wire: Agilent Technologies Inc. (NYSE: A) today announced the release of a new accessory kit that enables the company’s Dako Omnis system to analyze tissue

Informations relatives au nombre total de droits de vote et d'actions

Informations relatives au nombre total de droits de vote et d'actions

Riassunto: Pharnext presenterà i dati scientifici più aggiornati sui due suoi prodotti principali a diversi congressi scientifici internazionali | Business Wire

Riassunto: Pharnext presenterà i dati scientifici più aggiornati sui due suoi prodotti principali a diversi congressi scientifici internazionali | Business Wire: Notizie normative: Pharnext SA (FR0011191287 - ALPHA) (Paris:ALPHA), società biofarmaceutica impegnata in un approccio pionieristico allo sviluppo di

Los resultados de fase 2 de erdafitinib son prometedores para el tratamiento del cáncer urotelial metastásico | Business Wire

Los resultados de fase 2 de erdafitinib son prometedores para el tratamiento del cáncer urotelial metastásico | Business Wire: Las empresas farmacéuticas Janssen de Johnson & Johnson han anunciado hoy los resultados de un estudio de fase 2, que muestran que el tratamiento

BRITVIC

Dans une note de recherche intitulée "Starting to fizz", le bureau d'analyses allemand a indiqué qu'il avait également relevé son objectif de cours de 725 pence à 900 pence.

Britvic possède un portefeuille de marques, dont Tango, Teisseire, Fruité, Maguary et DaFruta, et produit également des boissons comme Pepsi, 7UP, SoBe et Mountain Dew en Angleterre et en Irlande suite à des accords exclusifs avec PepsiCo.

Amarin Sponsors Three Scientific Presentations Scheduled for American Diabetes Association Scientific Sessions

Amarin Sponsors Three Scientific Presentations Scheduled for American Diabetes Association Scientific Sessions

Calithera to Present at the Jefferies and JMP Securities Healthcare Conferences in June

Calithera to Present at the Jefferies and JMP Securities Healthcare Conferences in June

ESPERITE NV (ESP) LAUNCHS NEW AGAATA Dx, DIAGNOSTIC SYSTEM WITH MACHINE LEARNING CAPABILITIES FOR GENETIC CLINICAL LABORATORIES.

ESPERITE NV (ESP) LAUNCHS NEW AGAATA Dx, DIAGNOSTIC SYSTEM WITH MACHINE LEARNING CAPABILITIES FOR GENETIC CLINICAL LABORATORIES.